INVO Bioscience, Inc. (INVO): Broker Consensus Forecast

Management at INVO Bioscience, Inc. (INVO) is currently focusing on optimizing internal processes following the consolidation of assets, while the market consensus stands at 6.00. The company's price evolution reflects the dynamics of an asset that developed the INVOcell system for infertility treatment with an emphasis on biocompatible components. The business model's revenues are based on the sale of specialized capsules to clinics, offering patients a gentle alternative to traditional IVF.

INVO Bioscience, Inc. - INVO Price Target Chart (period 07/04/2022 - 04/28/2025)

Metric breakdowns and analytics for INVO Bioscience, Inc. (INVO)

- price and consensus price forecast:

Market Chart invobioscience.com|INVO - Price Target Chart

- stock exchange capitalization data:

Market Capitalization INVO Bio|INVO - Real Price to Acquire Entire Company

- business book valuation details:

Net Assets per Single Share INVO Bioscience|INVO - Company Book Value|Market-to-Book Ratio invobioscience.com|INVO - Aggregate Company Assets

- business debt structure and liquidity details:

- financial results and valuation multiples details:

INVO - Net Profit|Projected Future Earnings INVO Bioscience, Inc.|INVO - Price to Earnings Ratio|Future Price to Earnings invobioscience.com|INVO - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio INVO Bio|INVO - Operating profit before deduction of amortization|Earnings per one share for the last 12 months INVO Bioscience|INVO - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months invobioscience.com|INVO - Earnings growth in current year|Projected earnings per share growth rate for next year INVO Bioscience, Inc.

General company analysis:INVO - INVO Bioscience Inc.

Core merchandise of INVO Bioscience, Inc.

To objectively assess the commercial potential of INVO Bioscience, Inc. (INVO), it is critical for investors to monitor market expectations regarding the value of its unique INVOcell technology. The analysts' consensus price target aggregates disparate discounting models into a single stream, allowing this chart to identify the asset's fair value and protect capital from inflated quotes during periods of expert valuation updates.

Competing companies